Comparative Pharmacology
Head-to-head clinical analysis: NEO DELTA CORTEF versus NEO SYNALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO DELTA CORTEF versus NEO SYNALAR.
NEO-DELTA-CORTEF vs NEO-SYNALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with potent anti-inflammatory, immunosuppressive, and antiallergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Neomycin (aminoglycoside) binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis. Fluocinolone acetonide (corticosteroid) binds to glucocorticoid receptor, inducing anti-inflammatory proteins and suppressing inflammatory mediators.
1-2 drops into the conjunctival sac every 1-2 hours during the day and every 2 hours at night initially, then reduce frequency as inflammation subsides.
Apply a thin layer to affected area twice daily. Maximum 60 g per week.
None Documented
None Documented
Prednisolone: 2-4 hours; clinical context: adrenal suppression lasts 24-36 hours, requiring tapering
Approximately 2-4 hours for the corticosteroid component; clinical effect persists beyond due to cellular actions.
Renal: 70-80% as metabolites; biliary: 10-15%; fecal: <5%
Renal (primarily as metabolites): ~80%; biliary/fecal: ~20%.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic